The results revealed that the HFD mice had hepatic steatosis (Figure 1(a)), increased lipid accumulation (Figure 1(b)), enhanced NAFLD activity score (Figure 1(c)), and upregulated serum TC (Figure 1(d)), TG (Figure 1(d)), AST (Figure 1(e)), and ALT (Figure 1(e)) levels in comparison with the control mice. The gene discussed is GPT; the disease is Hepatic steatosis.